Karyopharm to host call on phase 3 myelofibrosis trial results

Key facts

• Karyopharm will host a conference call to discuss trial results.
• The trial is phase 3 and focuses on myelofibrosis.

Karyopharm is a pharmaceutical company. Myelofibrosis is a rare bone marrow cancer. The results of a phase 3 trial are crucial for potential drug approval and market entry.